“This study is the first to identify that NAAA, a previously unrecognized control node, can be effectively targeted by small-molecule therapeutics that inhibit this enzyme, and block the transition from acute to chronic pain,” said Daniele Piomelli, PhD, Distinguished Professor in the UCI School of Medicine Department of Anatomy & Neurobiology.
Previously unrecognized control point identified as target for drugs that block transition. A new study led by University of California, Irvine researchers is the first to reveal the specific molecular mechanism that controls the transition from acute to chronic pain, and identifies this mechanism as a critical target for disease-modifying medicines.
Findings from the study, titled “NAAA-regulated lipid signaling gov...
Read More
Recent Comments